Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia

Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic cytokines. In this study, forty patients in the chronic p...

Descripción completa

Detalles Bibliográficos
Autores principales: Catellani, Silvia, Pierri, Ivana, Gobbi, Marco, Poggi, Alessandro, Zocchi, Maria Raffaella
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078937/
https://www.ncbi.nlm.nih.gov/pubmed/21533122
http://dx.doi.org/10.1371/journal.pone.0018925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078937/
https://www.ncbi.nlm.nih.gov/pubmed/21533122
http://dx.doi.org/10.1371/journal.pone.0018925

Ejemplares similares